These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 16855120)

  • 21. Improving the measurement of health system output growth.
    Castelli A; Dawson D; Gravelle H; Street A
    Health Econ; 2007 Oct; 16(10):1091-107. PubMed ID: 17294495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health services utilization and cost utility analysis of a walking program for residential community elderly.
    Chen IJ; Chou CL; Yu S; Cheng SP
    Nurs Econ; 2008; 26(4):263-9. PubMed ID: 18777976
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
    Svatek RS; Lee JJ; Roehrborn CG; Lippman SM; Lotan Y
    Cancer; 2008 Mar; 112(5):1058-65. PubMed ID: 18186497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life, resource consumption and costs of spinal cord stimulation versus conventional medical management in neuropathic pain patients with failed back surgery syndrome (PROCESS trial).
    Manca A; Kumar K; Taylor RS; Jacques L; Eldabe S; Meglio M; Molet J; Thomson S; O'Callaghan J; Eisenberg E; Milbouw G; Buchser E; Fortini G; Richardson J; Taylor RJ; Goeree R; Sculpher MJ
    Eur J Pain; 2008 Nov; 12(8):1047-58. PubMed ID: 18359255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Costs and quality of life of multiple sclerosis in Germany.
    Kobelt G; Berg J; Lindgren P; Elias WG; Flachenecker P; Freidel M; König N; Limmroth V; Straube E
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S34-44. PubMed ID: 17310337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The cost per year of life gained: trends and internal contradictions].
    Smulders YM; Thijs A
    Ned Tijdschr Geneeskd; 2006 Nov; 150(45):2467-70. PubMed ID: 17137090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Costs and quality of life of multiple sclerosis in Italy.
    Kobelt G; Berg J; Lindgren P; Battaglia M; Lucioni C; Uccelli A
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S45-54. PubMed ID: 17310336
    [TBL] [Abstract][Full Text] [Related]  

  • 29. As good as it gets but good enough for which applications?
    Feeny D
    Med Decis Making; 2006; 26(4):307-9. PubMed ID: 16855119
    [No Abstract]   [Full Text] [Related]  

  • 30. Cost-effectiveness analyses of health promotion programs: a case study of smoking prevention and cessation among Dutch students.
    Vijgen SM; van Baal PH; Hoogenveen RT; de Wit GA; Feenstra TL
    Health Educ Res; 2008 Apr; 23(2):310-8. PubMed ID: 17675649
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Costs and quality of life of multiple sclerosis in Spain.
    Kobelt G; Berg J; Lindgren P; Izquierdo G; Sánchez-Soliño O; Pérez-Miranda J; Casado MA;
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S65-74. PubMed ID: 17310340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CEA is not a price control.
    Cohen J
    Health Aff (Millwood); 2007; 26(5):1505; author reply 1506-7. PubMed ID: 17848464
    [No Abstract]   [Full Text] [Related]  

  • 33. Cost-effectiveness analysis in severe mental illness: outcome measures selection.
    Stant AD; Buskens E; Jenner JA; Wiersma D; TenVergert EM
    J Ment Health Policy Econ; 2007 Jun; 10(2):101-8. PubMed ID: 17603150
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The cost per year of life gained: trends and internal contradictions].
    van Dam J
    Ned Tijdschr Geneeskd; 2007 Feb; 151(7):441; author reply 441-2. PubMed ID: 17343145
    [No Abstract]   [Full Text] [Related]  

  • 35. Costs and quality of life for patients with multiple sclerosis in Belgium.
    Kobelt G
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S24-33. PubMed ID: 17318662
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review article: Use of renal registry data for research, health-care planning and quality improvement: what can we learn from registry data in the Asia-Pacific region?
    Lim TO; Goh A; Lim YN; Morad Z
    Nephrology (Carlton); 2008 Dec; 13(8):745-52. PubMed ID: 19154324
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of integrated care for people with HIV, chronic mental illness and substance abuse disorders.
    Weaver MR; Conover CJ; Proescholdbell RJ; Arno PS; Ang A; Uldall KK; Ettner SL
    J Ment Health Policy Econ; 2009 Mar; 12(1):33-46. PubMed ID: 19346565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis.
    Kobelt G; Berg J; Lindgren P; Jönsson B
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S5-13. PubMed ID: 17310344
    [TBL] [Abstract][Full Text] [Related]  

  • 39. National health surveys and the behavioral model of health services use.
    Andersen RM
    Med Care; 2008 Jul; 46(7):647-53. PubMed ID: 18580382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Costs and quality of life in multiple sclerosis in The Netherlands.
    Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B
    Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.